Bicara Therapeutics (BCAX) Income Statement: Revenue & Earnings

Bicara Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Bicara Therapeutics Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022
Period Ending	Dec 2024	Dec 2023	Dec 2022
Revenue & Gross Profit
Revenue	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00
Operating Expenses
Research & Development	63.62	30.62	31.31
Selling, General & Administrative	18.77	9.27	6.34
Operating Expenses	82.39	39.89	37.66
Operating Income	-82.39	-39.89	-37.66
Other Income/Expense
Interest Income	14.58	1.31	0.00
Interest Expense	0.00	0.00	-0.11
Other Income/Expense	14.58	-13.41	-0.08
Income
Income Before Tax	-67.81	-51.98	-37.84
Income Tax Expense	0.19	0.01	0.00
Net Income	-68.00	-51.99	-37.85
Net Income - Continuous Operations	-68.00	-51.99	-37.85
Net Income - Discontinued Operations	0.00	0.00	0.00
EBITDA	-82.33	-39.87	-37.65
EBIT	-82.39	-39.89	-37.66
Depreciation & Amortization	0.06	0.02	0.01
Earnings Per Share
Basic EPS	-4.00	-2.00	-88.00
Diluted EPS	-4.00	-2.00	-88.00
Basic Shares Outstanding	16.81	33.98	0.43
Diluted Shares Outstanding	16.81	33.98	0.43